Form 8-K - Current report:
SEC Accession No. 0000950170-21-000941
Filing Date
2021-08-05
Accepted
2021-08-05 16:22:36
Documents
14
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K harp-20210805.htm   iXBRL 8-K 51740
2 EX-99.1 harp-20210805ex99_1.htm EX-99.1 206512
3 GRAPHIC img96809496_0.jpg GRAPHIC 3981
  Complete submission text file 0000950170-21-000941.txt   405806

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT harp-20210805_lab.xml EX-101.LAB 18297
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT harp-20210805_pre.xml EX-101.PRE 11629
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT harp-20210805.xsd EX-101.SCH 2449
7 EXTRACTED XBRL INSTANCE DOCUMENT harp-20210805_htm.xml XML 4909
Mailing Address 131 OYSTER POINT BOULEVARD SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 131 OYSTER POINT BOULEVARD SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-443-7400
Harpoon Therapeutics, Inc. (Filer) CIK: 0001708493 (see all company filings)

EIN.: 473458693 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38800 | Film No.: 211148586
SIC: 2836 Biological Products, (No Diagnostic Substances)